Insight Molecular Diagnostics Inc. shares rise 8.81% premarket after QIAGEN's solid Q2 2025 results.

Insight Molecular Diagnostics Inc. rose 8.81% in premarket trading. The company's stock price increase may be attributed to the positive financial results reported by QuidelOrtho, which showed a 4% growth in labs revenue and a 330 basis points improvement in adjusted EBITDA margin. Additionally, QIAGEN exceeded its outlook for Q2 2025 with solid growth, reporting a 7% increase in net sales and a 1.5 percentage point increase in the adjusted operating income margin.